A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of UK369,003 in Adult Male Subject With Erectile Dysfunction
Sponsor study identifier
interventional
300
1 country
39
Study Start
February 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2005
Date type not reportedThis date has not been verified as actual or estimated.
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
August 30, 2005
Actual (reported)September 1, 2005
Actual (reported)The time needed to obtain an erection hard enough to attempt sexual intercourse.
Proportion of responders based on successful erections Based on erections hard enough for sexual intercourse 15, 45 and 60 minutes post dose Proportion of good responders based on successful erections International Index of Erectile Function
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Pfizer Investigational Site
Birmingham, Alabama, 35205, United States
Pfizer Investigational Site
Birmingham, Alabama, 35209-5603, United States
Pfizer Investigational Site
Birmingham, Alabama, 35215, United States
Pfizer Investigational Site
Mesa, Arizona, 85201, United States
Pfizer Investigational Site
Mesa, Arizona, 85206, United States
Pfizer Investigational Site
Mesa, Arizona, 85213, United States
Pfizer Investigational Site
Tempe, Arizona, 85282, United States
Pfizer CT.gov Call Center
Pfizer
First Submitted
August 30, 2005
First Posted
September 1, 2005
Study Start
February 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
August 2005
Date type not reportedUrodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
Contact the study team to confirm eligibility.
Pfizer Investigational Site
Beverly Hills, California, 90212, United States
Pfizer Investigational Site
San Bernardino, California, 92404, United States
Pfizer Investigational Site
Torrance, California, 90505, United States
Pfizer Investigational Site
Waterbury, Connecticut, 06708, United States
Pfizer Investigational Site
Aventura, Florida, 33180, United States
Pfizer Investigational Site
Pembroke Pines, Florida, 33028, United States
Pfizer Investigational Site
St. Petersburg, Florida, 33709, United States
Pfizer Investigational Site
West Palm Beach, Florida, 33407, United States
Pfizer Investigational Site
Evansville, Indiana, 47714, United States
Pfizer Investigational Site
Fort Wayne, Indiana, 46825, United States
Pfizer Investigational Site
Jeffersonville, Indiana, 47130, United States
Pfizer Investigational Site
Metairie, Louisiana, 70002, United States
Pfizer Investigational Site
Metairie, Louisiana, 70006, United States
Pfizer Investigational Site
Milford, Massachusetts, 01757, United States
Pfizer Investigational Site
Kansas City, Missouri, 64114, United States
Pfizer Investigational Site
New Brunswick, New Jersey, 08903, United States
Pfizer Investigational Site
Albany, New York, 12206, United States
Pfizer Investigational Site
Endwell, New York, 13760, United States
Pfizer Investigational Site
New York, New York, 10016, United States
Pfizer Investigational Site
Raleigh, North Carolina, 27609-7216, United States
Pfizer Investigational Site
Raleigh, North Carolina, 27609, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103, United States
Pfizer Investigational Site
Beachwood, Ohio, 44122-5402, United States
Pfizer Investigational Site
Cincinnati, Ohio, 45212, United States
Pfizer Investigational Site
Cleveland, Ohio, 44122, United States
Pfizer Investigational Site
Bryan, Texas, 77802, United States
Pfizer Investigational Site
Sugar Land, Texas, 77478, United States
Pfizer Investigational Site
Salt Lake City, Utah, 84109, United States
Pfizer Investigational Site
West Jordan, Utah, 84088, United States
Pfizer Investigational Site
Norfolk, Virginia, 23502, United States
Pfizer Investigational Site
Richmond, Virginia, 23294, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, 53209, United States
This date has not been verified as actual or estimated.
Last Updated
July 25, 2006
Record last verified: 2006-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: